Cargando…

Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS

Quantifying neural activity in natural conditions (i.e. conditions comparable to the standard clinical patient experience) during the administration of psychedelics may further our scientific understanding of the effects and mechanisms of action. This data may facilitate the discovery of novel bioma...

Descripción completa

Detalles Bibliográficos
Autores principales: Castillo, Adelaida, Dubois, Julien, Field, Ryan M., Fishburn, Frank, Gundran, Andrew, Ho, Wilson C., Jawhar, Sami, Kates-Harbeck, Julian, M. Aghajan, Zahra, Miller, Naomi, Perdue, Katherine L., Phillips, Jake, Ryan, Wesley C., Shafiei, Mahdi, Scholkmann, Felix, Taylor, Moriah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356754/
https://www.ncbi.nlm.nih.gov/pubmed/37468572
http://dx.doi.org/10.1038/s41598-023-38258-8
_version_ 1785075343659368448
author Castillo, Adelaida
Dubois, Julien
Field, Ryan M.
Fishburn, Frank
Gundran, Andrew
Ho, Wilson C.
Jawhar, Sami
Kates-Harbeck, Julian
M. Aghajan, Zahra
Miller, Naomi
Perdue, Katherine L.
Phillips, Jake
Ryan, Wesley C.
Shafiei, Mahdi
Scholkmann, Felix
Taylor, Moriah
author_facet Castillo, Adelaida
Dubois, Julien
Field, Ryan M.
Fishburn, Frank
Gundran, Andrew
Ho, Wilson C.
Jawhar, Sami
Kates-Harbeck, Julian
M. Aghajan, Zahra
Miller, Naomi
Perdue, Katherine L.
Phillips, Jake
Ryan, Wesley C.
Shafiei, Mahdi
Scholkmann, Felix
Taylor, Moriah
author_sort Castillo, Adelaida
collection PubMed
description Quantifying neural activity in natural conditions (i.e. conditions comparable to the standard clinical patient experience) during the administration of psychedelics may further our scientific understanding of the effects and mechanisms of action. This data may facilitate the discovery of novel biomarkers enabling more personalized treatments and improved patient outcomes. In this single-blind, placebo-controlled study with a non-randomized design, we use time-domain functional near-infrared spectroscopy (TD-fNIRS) to measure acute brain dynamics after intramuscular subanesthetic ketamine (0.75 mg/kg) and placebo (saline) administration in healthy participants (n = 15, 8 females, 7 males, age 32.4 ± 7.5 years) in a clinical setting. We found that the ketamine administration caused an altered state of consciousness and changes in systemic physiology (e.g. increase in pulse rate and electrodermal activity). Furthermore, ketamine led to a brain-wide reduction in the fractional amplitude of low frequency fluctuations, and a decrease in the global brain connectivity of the prefrontal region. Lastly, we provide preliminary evidence that a combination of neural and physiological metrics may serve as predictors of subjective mystical experiences and reductions in depressive symptomatology. Overall, our study demonstrated the successful application of fNIRS neuroimaging to study the physiological effects of the psychoactive substance ketamine in humans, and can be regarded as an important step toward larger scale clinical fNIRS studies that can quantify the impact of psychedelics on the brain in standard clinical settings.
format Online
Article
Text
id pubmed-10356754
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-103567542023-07-21 Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS Castillo, Adelaida Dubois, Julien Field, Ryan M. Fishburn, Frank Gundran, Andrew Ho, Wilson C. Jawhar, Sami Kates-Harbeck, Julian M. Aghajan, Zahra Miller, Naomi Perdue, Katherine L. Phillips, Jake Ryan, Wesley C. Shafiei, Mahdi Scholkmann, Felix Taylor, Moriah Sci Rep Article Quantifying neural activity in natural conditions (i.e. conditions comparable to the standard clinical patient experience) during the administration of psychedelics may further our scientific understanding of the effects and mechanisms of action. This data may facilitate the discovery of novel biomarkers enabling more personalized treatments and improved patient outcomes. In this single-blind, placebo-controlled study with a non-randomized design, we use time-domain functional near-infrared spectroscopy (TD-fNIRS) to measure acute brain dynamics after intramuscular subanesthetic ketamine (0.75 mg/kg) and placebo (saline) administration in healthy participants (n = 15, 8 females, 7 males, age 32.4 ± 7.5 years) in a clinical setting. We found that the ketamine administration caused an altered state of consciousness and changes in systemic physiology (e.g. increase in pulse rate and electrodermal activity). Furthermore, ketamine led to a brain-wide reduction in the fractional amplitude of low frequency fluctuations, and a decrease in the global brain connectivity of the prefrontal region. Lastly, we provide preliminary evidence that a combination of neural and physiological metrics may serve as predictors of subjective mystical experiences and reductions in depressive symptomatology. Overall, our study demonstrated the successful application of fNIRS neuroimaging to study the physiological effects of the psychoactive substance ketamine in humans, and can be regarded as an important step toward larger scale clinical fNIRS studies that can quantify the impact of psychedelics on the brain in standard clinical settings. Nature Publishing Group UK 2023-07-19 /pmc/articles/PMC10356754/ /pubmed/37468572 http://dx.doi.org/10.1038/s41598-023-38258-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Castillo, Adelaida
Dubois, Julien
Field, Ryan M.
Fishburn, Frank
Gundran, Andrew
Ho, Wilson C.
Jawhar, Sami
Kates-Harbeck, Julian
M. Aghajan, Zahra
Miller, Naomi
Perdue, Katherine L.
Phillips, Jake
Ryan, Wesley C.
Shafiei, Mahdi
Scholkmann, Felix
Taylor, Moriah
Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS
title Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS
title_full Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS
title_fullStr Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS
title_full_unstemmed Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS
title_short Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS
title_sort measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using td-fnirs
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356754/
https://www.ncbi.nlm.nih.gov/pubmed/37468572
http://dx.doi.org/10.1038/s41598-023-38258-8
work_keys_str_mv AT castilloadelaida measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs
AT duboisjulien measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs
AT fieldryanm measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs
AT fishburnfrank measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs
AT gundranandrew measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs
AT howilsonc measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs
AT jawharsami measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs
AT katesharbeckjulian measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs
AT maghajanzahra measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs
AT millernaomi measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs
AT perduekatherinel measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs
AT phillipsjake measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs
AT ryanwesleyc measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs
AT shafieimahdi measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs
AT scholkmannfelix measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs
AT taylormoriah measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs